Arbutus Biopharma Corporation

(NASDAQ:ABUS)

Latest On Arbutus Biopharma Corporation (ABUS):

Date/Time Type Description Signal Details
2023-05-18 02:45 ESTNewsArbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023N/A
2023-05-04 21:46 ESTNewsArbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:45 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67MN/A
2023-04-25 14:16 ESTNewsArbutus sheds 18% after FDA clinical hold on antiviralN/A
2023-04-12 00:01 ESTNewsModerna wins appeals court ruling in Arbutus COVID vaccine patent disputeN/A
2023-04-05 02:46 ESTNewsPfizer, BioNTech dip as Arbutus charges violation of COVID vaccine patentsN/A
2023-03-02 12:31 ESTNewsArbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88MN/A
2023-03-02 12:30 ESTNewsArbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 22:16 ESTNewsArbutus Biopharma FY 2022 Earnings PreviewN/A
2023-02-23 11:16 ESTNewsArbutus Biopharma Corp.: Long Road Ahead For HBV CureN/A
2022-11-09 19:33 ESTNewsArbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23MN/A
2022-11-09 19:32 ESTNewsArbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 19:32 ESTNewsArbutus trades higher as Q3 net loss narrows, revenue grows on license dealN/A
2022-11-07 14:15 ESTNewsArbutus Biopharma (ABUS) presents at AASLD 2022 - SlideshowN/A
2022-11-03 05:01 ESTNewsArbutus gains after court denies Moderna motion to dismiss Covid-19 royalties caseN/A
2022-09-12 13:02 ESTNewsArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'N/A
2022-08-30 16:31 ESTNewsArbutus stock rises on US patent linked to hepatitis B therapy AB-729N/A
2022-08-04 22:47 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47MN/A
2022-08-04 22:46 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 16:46 ESTNewsArbutus Biopharma Q2 2022 Earnings PreviewN/A
2022-07-20 18:00 ESTNewsArbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trialN/A
2022-06-30 05:46 ESTNewsArbutus: 2 Key Catalysts To Look Forward To After EASL Data ReleaseN/A
2022-06-06 15:46 ESTNewsArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentN/A
2022-05-05 20:18 ESTNewsArbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16MN/A
2022-05-05 20:16 ESTNewsArbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 21:31 ESTNewsArbutus Biopharma Q1 2022 Earnings PreviewN/A
2022-03-19 19:34 ESTNewsArbutus sued to avoid patent dispute over Pfizer/BioNTech COVID-19 shotN/A
2022-03-14 23:02 ESTNewsArbutus price target raised at H.C. Wainwright on upcoming data readoutsN/A
2022-03-08 08:32 ESTNewsArbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestN/A
2022-03-04 00:32 ESTNewsArbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35MN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 12:45 ESTNewsArbutus Biopharma Q4 2021 Earnings PreviewN/A
2022-03-01 02:17 ESTNewsModerna hit by lawsuit as Arbutus, Genevant seek damages for use of COVID-19 vaccine patentsN/A
2022-01-24 16:17 ESTNewsArbutus Biopharma outlines milestones for 2022N/A
2021-12-22 11:31 ESTNewsRoivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy ArbutusN/A
2021-12-17 17:31 ESTNewsArbutus Biopharma: How Will Patent Win Impact Stock Outlook?N/A
2021-12-13 14:32 ESTNewsArbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%N/A
2021-12-08 01:33 ESTNewsArbutus identifies molecular targets for COVID-19 treatmentN/A
2021-12-01 16:46 ESTNewsModerna loses patent fight against Arbutus related to vaccines; Arbutus up 40%N/A
2021-12-01 16:46 ESTNewsArbutus chronic hepatitis B virus treatment shows antiviral activity in early-stage trialN/A
2021-12-01 16:46 ESTNewsRoivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%N/A
2021-11-20 03:16 ESTNewsArbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive InvestmentN/A
2021-11-19 06:32 ESTNewsAlnylam, Arrowhead gain on Novo bid to acquire DicernaN/A
2021-11-05 00:18 ESTNewsArbutus Biopharma EPS in-line, beats on revenueN/A
2021-11-05 00:16 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 03:02 ESTNewsArbutus Biopharma Q3 2021 Earnings PreviewN/A
2021-10-09 16:30 ESTNewsA look at the biopharmas developing new treatments for liver diseasesN/A
2021-10-07 03:30 ESTNewsModerna slips ahead of legal battle to invalidate COVID-19 vaccine patentsN/A
2021-09-22 20:29 ESTNewsArbutus Biopharma (ABUS) Investor Presentation - SlideshowN/A

About Arbutus Biopharma Corporation (ABUS):

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Quotes by TradingView

See Advanced Chart

General

  • Name Arbutus Biopharma Corporation
  • Symbol ABUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 76
  • Last Split Factor1:5
  • Last Split Date2010-11-04
  • Fiscal Year EndDecember
  • IPO Date2015-08-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arbutusbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.69
  • Price/Book (Most Recent Quarter) 2.44
  • Enterprise Value Revenue 56.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.86
  • Next Year EPS Estimate -$0.67
  • Next Quarter EPS Estimate -$0.23
  • Operating Margin -828%
  • Return on Assets -30%
  • Return on Equity -73%
  • Revenue 6.91 million
  • Earnings Per Share -$1.79
  • Revenue Per Share $0.09
  • Gross Profit -40567000
  • Quarterly Earnings Growth 47.5%
View More

Highlights

  • Market Capitalization 349.26 million
  • EBITDA -71643000
  • PE Ratio -9.48
  • Analyst Target Price $6.11
  • Book Value Per Share $1.23
View More

Share Statistics

  • Shares Outstanding 95.58 million
  • Shares Float 69.81 million
  • % Held by Insiders 2123%
  • % Held by Institutions 30.96%
  • Shares Short 3.27 million
  • Shares Short Prior Month 2.55 million
  • Short Ratio 0.94
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 3.05
  • 52 Week High $6.48
  • 52 Week Low $0.88
  • 50 Day Moving Average 3.96
  • 200 Day Moving Average 3.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arbutus Biopharma Corporation (ABUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arbutus Biopharma Corporation (ABUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$2.39 million-$0.23-$0.22-2.74%
2020-09-302020-11-05$N/A-$0.27-$0.22-26.07%
2020-06-302020-08-07$N/A-$0.25-$0.24-1.59%
2020-03-312020-05-11$1.49 million-$0.25-$0.3120.71%
2019-12-312020-03-05$1.62 million-$0.46-$0.36-26.6%
2019-09-302019-11-06$3.06 million-$1.50-$0.34-346.17%
2019-06-302019-08-05$653000-$0.46-$0.38-22.19%
2019-03-312019-05-06$679000-$0.47-$0.32-46.41%
2018-12-312019-03-07$1.68 million-$0.37-$0.406.98%
2018-09-302018-11-07$1.59 million-$0.49-$0.41-19.75%
2018-06-302018-08-02$1.24 million$0.01-$0.39102.54%
2018-03-312018-05-03$1.44 million-$0.36-$0.4010.76%
2017-12-312018-03-14$2.53 million-$0.67-$0.38-73.97%
2017-09-302017-11-02$6.89 million-$0.21-$0.3540.78%
2017-06-302017-08-03$1.04 million-$0.33-$0.4221.27%
2017-03-312017-05-04$235000-$0.34-$0.30-12.68%
2016-12-312017-03-21$-195000-$4.08-$0.40-932.74%
2016-09-302016-11-03$774000-$0.37-$0.5025.5%
2016-06-302016-08-04$309000-$2.47-$0.39-528.02%
2016-03-312016-05-04$603000-$0.31-$0.3716.46%
2015-12-312016-03-09$15.26 million-$0.10-$0.3974.17%
2015-09-302015-11-05$4.07 million-$0.12-$0.2958.62%
2015-06-302015-08-07$869000-$0.27-$0.296.9%
2015-03-312015-05-06$4.68 million-$0.40-$0.36-11.11%
2014-12-312015-03-12$4.35 million-$0.27-$0.283.57%
2014-09-302014-11-06$4.36 million-$0.39-$0.31-25.81%
2014-06-302014-08-13$1.81 million-$0.28-$0.25-12%
2014-03-312014-05-14$4.43 million-$0.91$0.16-668.75%
2013-12-312014-03-06$7.51 million-$0.10$0.06-266.67%
2013-09-302013-11-13$2.96 million-$0.42-$0.21-100%
2013-06-302013-08-12$2.79 million-$0.21
2013-03-312013-05-14$2.16 million-$0.18
2012-12-312013-03-27$3.91 million$2.70
2012-09-302012-11-13$3.1 million-$0.25
2012-06-302012-08-14$3.56 million-$0.14-$0.1612.5%
2012-03-312012-05-15$3.6 million-$0.25-$0.17-47.06%
2011-12-312012-03-27$3.66 million-$0.15
2011-09-302011-11-08$3.96 million-$0.12-$0.3060%
2011-06-302011-08-11$4.58 million-$0.33-$0.30-10%
2011-03-312011-05-10$4.48 million-$0.30-$0.3616.67%
2010-12-312011-03-30$6.21 million-$0.20-$0.2520%
2010-09-302010-11-15$4.34 million-$1.09-$0.20-445%
2010-06-302010-08-12$2.18 million-$0.40-$0.35-14.29%
2009-12-312010-03-17$4.27 million-$0.25-$0.3016.67%
2009-06-302009-08-12$3.25 million-$0.20-$0.15-33.33%
2009-03-312009-05-13$2.28 million-$0.20-$0.2520%
2008-12-312009-03-24$2.53 million-$0.35-$0.5030%
2007-12-312008-03-30$4.22 million$0.10$0.05100%
2007-09-302007-11-14$5.76 million$0.30$0.45-33.33%
2007-06-302007-08-08$2.82 million-$1.05-$0.30-250%

Arbutus Biopharma Corporation (ABUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arbutus Biopharma Corporation (ABUS) Chart:

Arbutus Biopharma Corporation (ABUS) News:

Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arbutus Biopharma Corporation (ABUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-09-1910CALL0 0873.02TRUE00
2025-09-1920CALL0 5624.7TRUE00
2025-09-1932.05CALL0 10420TRUE00
2025-09-1940.62CALL5 143384.42TRUE-0.28-0.31
2025-09-1950.04CALL16 86785.36FALSE-0.11-0.73
2025-09-1960.01CALL3 65123.93FALSE-0.04-0.8
2025-09-1970CALL0 0616.12FALSE00
2025-09-1980CALL0 0794.02FALSE00
2025-09-1910PUT0 00FALSE00
2025-09-1920PUT0 00FALSE00
2025-09-1930.05PUT0 1084237.71FALSE00
2025-09-1940.1PUT10 167125.43FALSE0.10
2025-09-1950PUT0 0153.96TRUE00
2025-09-1960PUT0 0448.91TRUE00
2025-09-1970PUT0 0355.69TRUE00
2025-09-1980PUT0 00TRUE00
2025-10-1710CALL0 0504.17TRUE00
2025-10-1721.63CALL0 49306.92TRUE00
2025-10-1732.01CALL0 1036183.43TRUE00
2025-10-1740.7CALL16 238182TRUE-0.45-0.39
2025-10-1750.33CALL34 386196.42FALSE-0.22-0.4
2025-10-1760.29CALL0 158222.55FALSE00
2025-10-1770.1CALL3 30117.2FALSE00
2025-10-1780.05CALL0 1286.33FALSE00
2025-10-1710PUT0 01000.68FALSE00
2025-10-1720PUT0 0502.94FALSE00
2025-10-1730.05PUT0 1029100.45FALSE00
2025-10-1740.15PUT0 39376.55FALSE00
2025-10-1750PUT0 0114.67TRUE00
2025-10-1760PUT0 0142.13TRUE00
2025-10-1770PUT0 00TRUE00
2025-10-1780PUT0 00TRUE00
2025-12-1910CALL0 00TRUE00
2025-12-1922.55CALL0 50150.96TRUE00
2025-12-1931.85CALL7 18123.8TRUE1.850
2025-12-1940.95CALL2 20077.86TRUE-0.31-0.25
2025-12-1950.75CALL0 306134.96FALSE00
2025-12-1960.35CALL0 57976.51FALSE00
2025-12-1970.19CALL2 6083.76FALSE00
2025-12-1980CALL0 0647.29FALSE00
2025-12-1910PUT0 00FALSE00
2025-12-1920PUT0 00FALSE00
2025-12-1930.18PUT0 67172.16FALSE00
2025-12-1940PUT0 0102.49FALSE00
2025-12-1950PUT0 0204.73TRUE00
2025-12-1960PUT0 0104.57TRUE00
2025-12-1970PUT0 064.27TRUE00
2025-12-1980PUT0 00TRUE00
2026-01-160.50CALL0 00TRUE00
2026-01-1610CALL0 5237.57TRUE00
2026-01-161.50CALL0 0155.52TRUE00
2026-01-1622.54CALL0 71168.66TRUE00
2026-01-162.52CALL8 847.37TRUE20
2026-01-1631.38CALL0 12479.67TRUE00
2026-01-163.51.34CALL5 170679.89TRUE1.340
2026-01-1641.29CALL0 1470TRUE00
2026-01-164.50.75CALL20 7171.65FALSE0.750
2026-01-1650.65CALL65 563279.7FALSE-0.1-0.13
2026-01-165.50.35CALL9 60864.14FALSE-0.18-0.34
2026-01-1660.4CALL0 2940114.79FALSE00
2026-01-1670.1CALL13 1360.21FALSE-0.2-0.67
2026-01-1680CALL0 0601.76FALSE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610PUT0 00FALSE00
2026-01-161.50PUT0 00FALSE00
2026-01-1620PUT0 00FALSE00
2026-01-162.50PUT0 0291.46FALSE00
2026-01-1630.06PUT18 1656.05FALSE0.060
2026-01-163.50.45PUT0 1621320.83FALSE00
2026-01-1640PUT0 15313.68FALSE00
2026-01-164.50PUT0 100118.35TRUE00
2026-01-1650.51PUT0 11236.47TRUE00
2026-01-165.50PUT0 0169.07TRUE00
2026-01-1660PUT0 1122.47TRUE00
2026-01-1670PUT0 0283.42TRUE00
2026-01-1680PUT0 00TRUE00
2026-03-2010CALL0 0148.5TRUE00
2026-03-2022.55CALL0 20126.54TRUE00
2026-03-2030.95CALL0 1177.51TRUE00
2026-03-2041.6CALL1000 120112.61TRUE1.60
2026-03-2051.3CALL655 5913116.09FALSE0.050.04
2026-03-2061.35CALL2172 2001140.34FALSE0.630.88
2026-03-2070CALL0 00FALSE00
2026-03-2080CALL0 00FALSE00
2026-03-2010PUT0 00FALSE00
2026-03-2020PUT0 00FALSE00
2026-03-2030PUT0 0142.76FALSE00
2026-03-2040.6PUT2399 35570.53FALSE0.050.09
2026-03-2050PUT0 0128.06TRUE00
2026-03-2060PUT0 0125.01TRUE00
2026-03-2070PUT0 091.3TRUE00
2026-03-2080PUT0 0101.8TRUE00
2027-01-152.52CALL0 43111.98TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-153.52CALL0 27193.34TRUE00
2027-01-1541.3CALL0 166168.16TRUE00
2027-01-154.51.32CALL0 2179.23FALSE00
2027-01-1551.75CALL2 1693.52FALSE1.750
2027-01-155.51.63CALL2 33093.7FALSE0.130.09
2027-01-1571.2CALL0 92181.5FALSE00
2027-01-152.50PUT0 00FALSE00
2027-01-1530.79PUT0 2498.97FALSE00
2027-01-153.50PUT0 4173.12FALSE00
2027-01-1540.5PUT0 3209.44FALSE00
2027-01-154.50PUT0 00TRUE00
2027-01-1551.5PUT0 940TRUE00
2027-01-155.51.9PUT0 120313.44TRUE00
2027-01-1572.1PUT0 250TRUE00

Latest ABUS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST400$2.39
Jun 13, 2022 7:59 PM EST200$2.39
Jun 13, 2022 7:59 PM EST1000$2.39
Jun 13, 2022 7:59 PM EST200$2.385
Jun 13, 2022 7:59 PM EST17$2.385

Arbutus Biopharma Corporation (ABUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1447028/000000000019016815/0000000000-19-016815-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000089542120000423/0000895421-20-000423-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000089924319019548/0000899243-19-019548-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000004/0000903423-19-000004-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000012/0000903423-19-000012-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000288/0000903423-19-000288-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000298/0000903423-19-000298-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000299/0000903423-19-000299-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583619000122/0000935836-19-000122-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583620000133/0000935836-20-000133-index.htm
2018-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000104746918007755/0001047469-18-007755-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746919002498/0001047469-19-002498-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746920002560/0001047469-20-002560-index.htm
2018-12-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074106/0001104659-18-074106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074112/0001104659-18-074112-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919006779/0001104659-19-006779-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919008025/0001104659-19-008025-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919023074/0001104659-19-023074-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919030387/0001104659-19-030387-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040421/0001104659-19-040421-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040422/0001104659-19-040422-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040589/0001104659-19-040589-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040594/0001104659-19-040594-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040598/0001104659-19-040598-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040934/0001104659-19-040934-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919045102/0001104659-19-045102-index.htm
2019-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919059987/0001104659-19-059987-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919070902/0001104659-19-070902-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465920020447/0001104659-20-020447-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000110465920100169/0001104659-20-100169-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001084/0001123292-18-001084-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001085/0001123292-18-001085-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001115/0001123292-18-001115-index.htm
2018-12-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001125/0001123292-18-001125-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/0001123292-19-000431-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000432/0001123292-19-000432-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000435/0001123292-19-000435-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000436/0001123292-19-000436-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000437/0001123292-19-000437-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000438/0001123292-19-000438-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000910/0001123292-19-000910-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000911/0001123292-19-000911-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034587/0001144204-19-034587-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034595/0001144204-19-034595-index.htm
2018-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006281/0001171843-18-006281-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006907/0001171843-18-006907-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007089/0001171843-18-007089-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007727/0001171843-18-007727-index.htm
2018-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318008152/0001171843-18-008152-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319001586/0001171843-19-001586-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319002996/0001171843-19-002996-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004042/0001171843-19-004042-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004412/0001171843-19-004412-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319005142/0001171843-19-005142-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184320007636/0001171843-20-007636-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193243/0001193125-19-193243-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193262/0001193125-19-193262-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000120919119041996/0001209191-19-041996-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000006/0001447028-19-000006-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000010/0001447028-19-000010-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000015/0001447028-19-000015-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000018/0001447028-19-000018-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/0001447028-19-000025-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000031/0001447028-19-000031-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000049/0001447028-19-000049-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000050/0001447028-19-000050-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000051/0001447028-19-000051-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000052/0001447028-19-000052-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000053/0001447028-19-000053-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/0001447028-19-000054-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000055/0001447028-19-000055-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000056/0001447028-19-000056-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000057/0001447028-19-000057-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000060/0001447028-19-000060-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000064/0001447028-19-000064-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000069/0001447028-19-000069-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000071/0001447028-19-000071-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000144702819000078/0001447028-19-000078-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000081/0001447028-19-000081-index.htm
2020-01-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000004/0001447028-20-000004-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000006/0001447028-20-000006-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000009/0001447028-20-000009-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000024/0001447028-20-000024-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000025/0001447028-20-000025-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000026/0001447028-20-000026-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/0001447028-20-000027-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000028/0001447028-20-000028-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000029/0001447028-20-000029-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000030/0001447028-20-000030-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000031/0001447028-20-000031-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000035/0001447028-20-000035-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000038/0001447028-20-000038-index.htm
2020-03-0610-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000041/0001447028-20-000041-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000043/0001447028-20-000043-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000046/0001447028-20-000046-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000049/0001447028-20-000049-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000052/0001447028-20-000052-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/0001447028-20-000063-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000064/0001447028-20-000064-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000065/0001447028-20-000065-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000066/0001447028-20-000066-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000067/0001447028-20-000067-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000068/0001447028-20-000068-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000069/0001447028-20-000069-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000071/0001447028-20-000071-index.htm
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000078/0001447028-20-000078-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000100/0001447028-20-000100-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/0001447028-20-000118-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000121/0001447028-20-000121-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000124/0001447028-20-000124-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000126/0001447028-20-000126-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000129/0001447028-20-000129-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000135/0001447028-20-000135-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000140/0001447028-20-000140-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000143/0001447028-20-000143-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000144/0001447028-20-000144-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000150/0001447028-20-000150-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315219001945/0001493152-19-001945-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315220002406/0001493152-20-002406-index.htm
2018-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-08-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001171/0001567619-18-001171-index.htm
2018-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003916/0001567619-18-003916-index.htm
2018-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003919/0001567619-18-003919-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004374/0001567619-18-004374-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004376/0001567619-18-004376-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004378/0001567619-18-004378-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004380/0001567619-18-004380-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/0001628280-18-013909-index.htm
2020-01-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520000069/9999999995-20-000069-index.htm
2020-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520002943/9999999995-20-002943-index.htm
2020-07-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004141/9999999997-20-004141-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004563/9999999997-20-004563-index.htm

Arbutus Biopharma Corporation (ABUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-23Michael J. McElhaughChief Business OfficerSell20,000.005.01100,200.001,367,457.00https://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2018-08-13Michael J. SofiaChief Scientific OfficerSell4,250.009.5140,435.781,499,153.00https://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-11-28Mark J. MurrayDirectorBuy25,000.001.3533,750.00341,396.00https://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm